Roche tests new weapon against advanced cancers

NCT ID NCT05240898

Summary

This early-stage study tested a new cancer drug called RO7623066, both alone and combined with other treatments, in 116 patients with advanced solid tumors. The main goals were to find the safest dose and see how the body processes the drug. Researchers also looked for early signs that the treatment might help control cancer growth.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Barbara Ann Karmanos Cancer Institute

    Detroit, Maine, 48201-2013, United States

  • Cleveland Clinic,

    Cleveland, Ohio, 44195, United States

  • Dana-Farber Cancer Institute

    Boston, Massachusetts, 02215, United States

  • Hackensack University Medical Center

    Hackensack, New Jersey, 07601, United States

  • Mary Crowley Medical Research Center

    Dallas, Texas, 75230, United States

  • Oregon Health & Science University

    Portland, Oregon, 97239, United States

  • Rhode Island Hospital

    Providence, Rhode Island, 02906, United States

  • South Texas Accelerated Research Therapeutics (START)

    San Antonio, Texas, 98229, United States

  • South Texas Accelerated Research Therapeutics (START) - Midwest Location

    Grand Rapids, Michigan, 49546, United States

  • The Ohio State University Comprehensive Cancer Center

    Columbus, Ohio, 43210, United States

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas, 77030-4009, United States

  • University of California Irvine Medical Center

    Orange, California, 92868, United States

  • University of Oklahoma Health Sciences Center

    Oklahoma City, Oklahoma, 73104, United States

  • University of Virginia Health System

    Charlottesville, Virginia, 22908, United States

  • Yale School of Medicine

    New Haven, Connecticut, 06510-3206, United States

Conditions

Explore the condition pages connected to this study.